Experimental: Part 1a
Solid Tumors with Any WNT-Pathway Activating Mutation (WPAM) or Microsatellite Stable (MSS) Colorectal Cancer (Irrespective of WPAM Status)
Drug: FOG-001
FOG-001 will be administered IV once weekly at assigned doses in continuous cycles of 28 days
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
